|

Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles

RECRUITINGSponsored by Kolding Sygehus
Actively Recruiting
SponsorKolding Sygehus
Started2024-11-15
Est. completion2029-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.

Eligibility

Age: 18 Years+Healthy volunteers accepted
SLE patients with kidney involvement

Inclusion criteria:

* \> 18 years old
* Fulfilling the 2019 EULAR/ACR classification criteria
* Positive autoantibodies, medical history and obejctive examination compatible with SLE
* Referred to kidney biopsy

Exclusion criteria:

* Lack of ability or willingness to provide informed consent
* Significant comorbidity, which is considered to potentially impact the outcome

SLE patients with no sign of kidney disease

Inclusion criteria:

* \> 18 years old
* Fulfilling the 2019 EULAR/ACR classification criteria
* Positive autoantibodies, medical history and obejctive examination compatible with SLE
* Normal plasma creatinine
* Urine albumine/creatinine \< 100 mg/g

Exclusion criteria:

* Lack of ability or willingness to provide informed consent
* Significant comorbidity, which is considered to potentially impact the outcome

Healthy controls:

Inclusion criteria:

* \> 18 years old
* No known kidney disease

Exclusion criteria:

* Lack of ability or willingness to provide informed consent
* Urine albumin-creatinine ratio \> 100 mg/g or proteinuria \> 100 mg/day
* Postive autoantibodies
* Significant comorbidity, which is considered to potentially impact the outcome

Biopsy control:

Inclusion criteria:

* \> 18 years old
* Negative autoantibiodies and immunoglobulines
* Referred to kidney biopsy

Exclusion criteria:

* Lack of ability or willingness to provide informed consent
* Significant comorbidity, which is considered to potentially impact the outcome

Conditions2

LupusSystemic Lupus Erythematosus Nephritis

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.